Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing. Circulation. 1999;100:2431 6. S7.9-38. Eldar M, Griffin JC, Van Hare GF, et al. Combined use of beta-adren- ergic blocking agents and long-term cardiac pacing for patients with the long QT syndrome. J Am Coll Cardiol. 1992;20:830 7. S7.9-39. Moss AJ, Liu JE, Gottlieb S, et al. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation. 1991;84:1524 9. S7.9-40. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta- blockers in long-QT syndrome type 1: contribution of noncompli- ance and QT-prolonging drugs to the occurrence of beta-blocker treatment failures. Circulation. 2009;119:215 21. 7.9.1. Specific Cardiac Channelopathy Syndromes 7.9.1.1. Congenital Long QT Syndrome S7.9.1.1-1. Abu-Zeitone A, Peterson DR, Polonsky B, et al. Efficacy of differ- ent beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. 2014;64:1352 8. S7.9.1.1-2. Goldenberg I, Bradley J, Moss A, et al. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. J Cardiovasc Electrophysiol. 2010;21:893 901. S7.9.1.1-3. Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limita- tions of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616 23. S7.9.1.1-4. Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. J Am Coll Cardiol. 2007;49:329 37. S7.9.1.1-5. Vincent GM, Schwartz PJ, Denjoy I, et al. High efficacy of beta- blockers in long-QT syndrome type 1: contribution of noncompli- ance and QT-prolonging drugs to the occurrence of beta-blocker treatment failures. Circulation. 2009;119:215 21. S7.9.1.1-6. Chorin E, Hu D, Antzelevitch C, et al. Ranolazine for congeni- tal long-qt syndrome type III: experimental and long-term clinical data. Circ Arrhythm Electrophysiol. 2016;9:e004370. S7.9.1.1-7. Chorin E, Taub R, Medina A, et al. 